Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer

• Main Authors: Wong A.L.A., Sundar R., Wang T.-T., Ng T.-C., Zhang B., Tan S.-H., Soh T.I.P., Pang A.S.L., Tan C.-S., Ow S.G.W., Wang L., Mogro J., Ho J., Jeyasekharan A.D., Huang Y., Thng C.-H., Chan C.-W., Hartman M., Iau P., Buhari S.A., Goh B.-C., Lee S.-C.
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: cyclophosphamide; doxorubicin; sunitinib; anthracycline; antineoplastic agent; contrast medium; indole derivative; pyrrole derivative; tumor marker; adult; aged; anemia; Article; breast cancer; cancer chemotherapy; clinical article; controlled study; drug efficacy; drug response; drug safety; febrile neutropenia; female; fever; human; human tissue; immunohistochemistry; lethargy; leukopenia; lymph vessel; multiple cycle treatment; neutropenia; nuclear magnetic resonance imaging; phase 1 clinical trial; phase 2 clinical trial; randomized controlled trial; stomatitis; breast tumor; clinical trial; disease free survival; drug administration; middle aged; neoadjuvant therapy; preoperative period; treatment outcome; Adult; Aged; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Contrast Media; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Preoperative Period; Pyrroles; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174106
• Institution: National University of Singapore

10.18632/oncotarget.11596